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It has long been recognized that the p53 tumor suppressor plays 
a pivotal role in preventing cancer (for review see Vogelstein 
et al., 2000). Multiple lines of evidence support this tenet: 
(1) p53 is the most commonly mutated gene in human cancer; 
(2) mice lacking p53 invariably develop tumors by  8 mo of 
age; and (3) individuals who inherit a p53 mutation are highly 
tumor prone, usually developing a malignancy during child-
hood or as a young adult. The latter situation is referred to as 
Li-Fraumeni syndrome, which is characterized by a predisposi-
tion to diverse   tumor types, including osteosarcomas. With no 
uncertainty, p53 is essential for blocking tumor development. 
How it does so lies within its ability to positively and negatively 
regulate gene   expression. p53 responds to various cell stresses 
such as DNA damage and oncogene activation by inducing 
downstream target genes to block cell proliferation or to induce 
apoptosis.   Collectively, p53 transcriptional activities literally 
impact life and death by maintaining normal cell growth and 
eliminating abnormal, potentially tumorigenic cells.
The signaling pathways activated by p53 are negatively 
controlled by Mdm2, which is a p53 target gene that encodes an 
E3 ubiquitin ligase (for review see Michael and Oren, 2002). 
As p53 levels increase, Mdm2 gene expression is concomitantly 
  induced. Consequently, Mdm2 protein binds to and represses 
p53 function, in part, by interfering with its association with tran-
scription factors and by targeting it for proteasomal degradation. 
Homozygous deletion of Mdm2 results in early embryonic 
  lethality as a result of uncontrolled p53-mediated cell cycle 
  arrest and apoptosis. Remarkably, crossing Mdm2-defi  cient 
mice onto a p53 knockout background completely rescues 
the lethality, allowing the generation of Mdm2
–/–; p53
–/– double 
knockout animals. These fi  ndings establish a critical autoregu-
latory negative feedback loop between p53 and Mdm2 that 
keeps p53 activity in check. The balance between p53 and 
Mdm2 has clinical relevance as well. A substantial percentage 
of human soft tissue sarcomas and other tumor types harbor 
wild-type p53 alleles that are inactive because of the amplifi  ca-
tion and overexpression of MDM2. A recurring theme in human 
cancer is the loss of p53 function either directly through 
mutation of the p53 gene or by perturbations within the p53 
signaling pathway.
Earlier work pioneered by Varda Rotter and colleagues 
and subsequently confi  rmed by others implicated p53 in the 
control of differentiation in a variety of cell types (for review 
see Almog and Rotter, 1997). For example, the enforced expres-
sion of wild-type p53 in murine L12 cells promotes B cell matu-
ration and the production of antibodies (Shaulsky et al., 1991). 
The common conclusion of these studies was that p53 promotes 
differentiation, which makes perfect sense for a protein that sup-
presses cell proliferation in light of the general understanding 
that there exists an inverse correlation between cell growth and 
differentiation. As cells undergo differentiation, they exit the 
cell cycle and cease to proliferate. However, it is important to 
note that many of these studies relied on established cell lines to 
study the involvement of p53 in cell differentiation.
Two independent studies (see Lengner et al. on p. 909 
of this issue; Wang et al., 2006) have addressed the role of p53 
in bone differentiation in mouse models. In one case, Wang 
et al. (2006) examined skeletal structure and bone metabolism 
in p53 knockout mice. Conversely, Lengner et al. (2006) 
analyzed the effects of hyperactive p53 on bone formation 
caused by the conditional deletion of Mdm2 in osteoblasts. 
Surprisingly, and in contrast to the in vitro studies (for review 
see Almog and Rotter, 1997), both groups came to the same 
conclusion that p53 suppresses differentiation. Specifi  cally, 
p53
–/– osteoblasts displayed a marked propensity to differentiate, 
which was manifested by a modest but signifi  cant increase 
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A series of in vitro tissue culture studies indicated that 
the p53 tumor suppressor promotes cellular differentiation, 
which could explain its role in preventing cancer. Quite sur-
prisingly, however, two new in vivo studies (Lengner et al., 
2006; Wang et al., 2006) provide genetic evidence that 
p53 blocks osteoblast differentiation and bone development. 
These interesting results and their biological and clinical 
implications are the focus of this comment.
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in bone formation and bone density in adult p53 knockout 
mice. Consistent with these results, the conditional deletion of 
Mdm2 in osteoblasts interfered with terminal differentiation, 
leading to late stage embryonic lethality, where the embryos 
displayed more porous and shorter bones. These findings 
suggest that the interplay between p53 and Mdm2 could either 
positively or negatively impact bone development.
Osteoblasts originate from undifferentiated mesenchymal 
stem cells through the coordinated expression of transcriptional 
regulators that serve as “master switches” of differentiation. 
In particular, the transcription factors Runx2 and Osterix play 
a crucial role in modulating the commitment of mesenchymal 
stem cells toward the osteoprogenitor lineage (Ducy et al., 1999; 
Nakashima et al., 2002). Analysis of Osterix-null mice shows 
that Osterix is genetically downstream of Runx2. The studies 
of both Wang et al. (2006) and Lengner et al. (2006) provide 
com  pelling evidence that p53 suppresses osteoblast differentia-
tion by repressing the expression of either Runx2 or Osterix. 
The subtle discrepancy that exists between the two studies 
(whether Runx2 or Osterix is the target of p53 action) may be 
related to how p53 activity is targeted and whether this mecha-
nism alters the stage of cell differentiation. In either case, the 
concept that the absence of a tumor suppressor gene can 
enhance cell proliferation while favoring the differentiation of 
mesenchymal stem cells is intriguing but counterintuitive. It is 
likely that p53-defi  cient osteoprogenitors can still exit the cell 
cycle upon terminal differentiation, which may be enhanced as 
a result of the elevated expression of Runx2 and Osterix.
The activity of osteoblasts and osteoclasts must be coordi-
nated to have a balance between bone formation and bone 
resorption. A coculture system of osteoblasts and hematopoietic 
cells has established the concept that osteoblasts are pivotally in-
volved in osteoclast development through cell-to-cell contact. 
Proteins involved in this interaction have recently been identifi  ed 
(for review see Boyle et al., 2003). One such example is the 
  receptor activator of nuclear factor κB ligand (RANKL), a 
membrane-bound protein of the TNF ligand family that is 
expressed on the osteoblast cell surface. RANKL plays a major 
role in osteoclast differentiation along with macrophage 
colony–stimulating factor (MCSF; for review see Boyle et al., 
2003). The study by Wang et al. (2006) for the fi  rst time reports 
the novel fi  nding that Osterix positively regulates the level of 
MCSF without affecting RANKL expression. Consequently, 
p53
−/− osteoblasts, which express elevated levels of Osterix, 
promoted the differentiation of osteoclasts in a coculture assay. 
Therefore, the loss of p53 stimulates both bone formation and 
bone resorption, with a net anabolic effect (Fig. 1). Collectively, 
these fi  ndings further underline the complexity of osteoblast–
osteoclast cross talk and its critical importance in maintaining 
bone homeostasis.
Bone undergoes continuous turnover throughout life 
(in both mice and humans), which is essential for maintaining 
normal bone health. Thus, genetic modifi  ers of osteoblast pro-
liferation, differentiation, and osteoblast-associated osteoclas-
togenesis are likely to play an important role in normal and 
pathologic bone biology. For example, the p53 signaling path-
way identifi  ed here serves as a genetic determinant of bone 
mass. It follows, then, that disorders of osteoporosis or bone 
response to injury, such as fracture healing, may be infl  uenced 
by p53 functional activity. Interestingly, an Mdm2 promoter 
polymorphism has been recently identifi   ed that determines 
Mdm2 expression and, therefore, p53 activity and susceptibility 
to cancer (Bond et al., 2004). Likewise, a p53 polymorphism 
(Arg/Pro at amino acid 72) impacts its ability to induce apo-
ptosis and function as a tumor suppressor (Dumont et al., 2003). 
Whether these naturally occurring and seemingly subtle genetic 
variations impact bone differentiation and development should 
be explored. The fact that the loss of p53 through point muta-
tions or deletions can promote the development of osteosarcoma 
is consistent with this possibility. In summary, the implications 
of the fi  ndings reported in the Wang et al. (2006) and Lengner 
et al. (2006) studies identify p53 and Mdm2 as new molecular 
targets that could be exploited to favorably alter bone modeling 
and remodeling.
It is fascinating that the p53 knockout mouse has been 
  extensively studied for more than a decade before the aforemen-
tioned studies uncovered its osteosclerotic phenotype. These 
fi  ndings clearly establish p53 as a negative regulator of osteo-
blast differentiation both in vitro and in vivo. Whether p53 plays 
a role in the differentiation of other cell types, including possible 
positive effects, and how it may do so remains to be determined.
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